Laboratory Corp of America (Labcorp) has announced that it plans to separate its clinical development business into an independent, publicly-traded contract research organisation (CRO). The move will return Labcorp to its core lab testing business and central laboratory network and will allow each company to "benefit from its own capital structure, enhanced investor alignment through a more targeted investment opportunity and a differentiated value proposition," said chief executive Adam Schechter on a conference call.